



**Neuren (NEU) - ASX Announcement**

**26 March 2020**

## **New international institutional shareholder acquires 14% of Neuren**

**Melbourne, Australia, 26 March 2020:** Neuren Pharmaceuticals (ASX: NEU) today reported that funds managed by Karst Peak Capital Limited (Karst Peak) have acquired approximately 14% of Neuren's shares. Karst Peak is an international investment management firm, focused on equity investments in healthcare and technology.

Neuren Executive Chairman Richard Treagus commented: "We are very pleased to welcome Karst Peak as a new shareholder with substantial life sciences expertise and international reach. This significantly enhances the international and institutional make-up of Neuren's share register as we approach a period of great opportunity for both trofinetide and NNZ-2591."

### **About Neuren**

Neuren is developing new therapies for neurodevelopmental disorders with high unmet need, utilizing synthetic analogs of neurotrophic peptides that occur naturally in the brain. Trofinetide is currently in a Phase 3 clinical trial for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs have each received Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Neuren has granted an exclusive license to ACADIA Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, whilst retaining all rights outside North America. Neuren is advancing the development of NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins syndromes, each of which has received Orphan Drug designation in the United States.

### **Contact:**

Jon Pilcher, CFO & Company Secretary: [jpilcher@neurenpharma.com](mailto:jpilcher@neurenpharma.com); +61 438 422 271

### **ASX Listing Rules information**

This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

### *Forward-looking Statements*

*This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.*